NCT03264456View on ClinicalTrials.gov

Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

January 30, 2019

Study Completion Date

February 13, 2020

Conditions
Prostate Cancer
Interventions
DIAGNOSTIC_TEST

[18F] Fluciclovine PET/MRI

\[18F\] fluciclovine PET/MRI

DRUG

[18F] fluciclovine

\[18F\] fluciclovine

Trial Locations (1)

35249

University of Alabama at Birmingham Medical Center, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT03264456 - Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI | Biotech Hunter | Biotech Hunter